Trial Profile
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; Inbakicept (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms QUILT-3.032
- Sponsors ImmunityBio
- 05 Feb 2024 According to an ImmunityBio media release, data from this study were published by the peer-reviewed journal Urology Practice.
- 05 Feb 2024 Results (May 16, 2022 data cutoff) published in an ImmunityBio Media Release.
- 26 Oct 2023 According to an ImmunityBio media release, company announced that the U.S. Food and Drug Administration (FDA) has accepted for review resubmission of its Biologics License Application (BLA) for N-803 for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease, and considered it as a complete response to the FDA's May 9, 2023 complete response letter. The FDA has set a user fee goal date (PDUFA date) of April 23, 2024.